CAJ | 학술논문

目的：观察胸腺五肽辅助治疗难治性肺炎支原体肺炎的临床疗效及对机体免疫功能的影响,以期为临床寻找一种安全有效的治疗方案。方法选取110例难治性肺炎支原体肺炎患儿为研究对象,随机分为观察组和对照组各55例,对照组给予大环内酯类抗生素序贯治疗,观察组在此基础上给予胸腺五肽治疗,观察患儿临床症状改善情况,检测 T 细胞亚群和免疫球蛋白水平及不良反应。结果与对照组比较,治疗组患儿在咳嗽消失时间、喘息消失时间、体温恢复正常时间、肺部啰音消失时间和胸部 X 线阴影消失时间明显降低(均 P <0.01)；治疗后,治疗组CD3+、CD4+和 CD4+/CD8+水平均明显高于治疗前和对照组,而 CD8+水平均明显低于治疗前和对照组(均 P <0.01),两组 IgA,IgG 和 IgM 治疗后水平上升,与治疗前相比差异均无统计学意义(均 P >0.05),两组患儿均未发生明显的不良反应。结论胸腺五肽辅助治疗难治性肺炎支原体肺炎可显著增强患儿免疫功能,提高临床治疗效果,值得临床推广使用。
목적：관찰흉선오태보조치료난치성폐염지원체폐염적림상료효급대궤체면역공능적영향,이기위림상심조일충안전유효적치료방안。방법선취110례난치성폐염지원체폐염환인위연구대상,수궤분위관찰조화대조조각55례,대조조급여대배내지류항생소서관치료,관찰조재차기출상급여흉선오태치료,관찰환인림상증상개선정황,검측 T 세포아군화면역구단백수평급불량반응。결과여대조조비교,치료조환인재해수소실시간、천식소실시간、체온회복정상시간、폐부라음소실시간화흉부 X 선음영소실시간명현강저(균 P <0.01)；치료후,치료조CD3+、CD4+화 CD4+/CD8+수평균명현고우치료전화대조조,이 CD8+수평균명현저우치료전화대조조(균 P <0.01),량조 IgA,IgG 화 IgM 치료후수평상승,여치료전상비차이균무통계학의의(균 P >0.05),량조환인균미발생명현적불량반응。결론흉선오태보조치료난치성폐염지원체폐염가현저증강환인면역공능,제고림상치료효과,치득림상추엄사용。
ABSTRACT:Objective To observe thymopentin in adjuvant therapy for refractory mycoplasma pneumonia and influence on the immune function in children,with a view to find a safe and effective clinical treatment.Methods The study involved 1 10 cases of children with refractory mycoplasma pneumonia who were randomly divided into observation group and control group ,55 cases in each group.Control group received sequential treatment of macrolide antibiotics,while observation group was given thymopetidum on the basis of conventional treatment.The improvement of clinical symptoms was observed,the T cell subsets and immunoglobulin levels and adverse reactions were detected. Results Compared with control group,treatment group showed significantly decrease in cough time,breathing spell time,body temperature returned to normal,pulmonary rales time and chest X-ray shadow time(P < 0.01 );after treatment,the CD3 + ,CD4 + and CD4 +/CD8 + levels in observation group were significantly higher than those before treatment and control group,but CD8 + in observation group was significantly lower than that that before treatment and control groups(P < 0.01 ).IgA,IgG and IgM in both groups raised after treatment,but compared with before treatment,the differences of two groups were not significant (P >0.05).The two groups of children did not showed significant adverse reactions.Conclusion Thymopentin in adjuvant treatment of refractory mycoplasma pneumonia of children can significantly enhance immune function, improve clinical outcomes,which is worthy of clinical popularization.